Klinefelter syndrome beyond hypogonadism: multisystem manifestations and a framework for clinical surveillance
A review argues Klinefelter syndrome wrecks more than fertility, yet up to 75% of cases go undiagnosed
Journal: Frontiers in Endocrinology | Published: 2026-06-24 | Type: Journal Article, Review | PMID:42422432Authors: Anaforoğlu İnan (Department of Endocrinology and Metabolism, School of Medicine, Acıbadem Mehmet Ali Aydınlar University)
Funding/COI: Funding not listed. No conflicts of interest declared.
Summary
This is a single-author narrative review arguing that Klinefelter syndrome (47,XXY, affecting roughly 1 in 450-600 male births) should be understood as a multisystem disorder, not just a cause of infertility and low testosterone. It compiles prior literature on metabolic, cardiovascular, thromboembolic, skeletal, thyroid, oncologic, autoimmune, and neurocognitive complications, and proposes a structured surveillance framework. No new patient data are presented; this is a synthesis of existing published findings.
Claims
KS occurs in approximately 1 in 450-600 male births, with 47,XXY the majority karyotype.
Up to 75% of individuals with KS remain undiagnosed throughout their lives.
KS carries elevated thromboembolic and cardiovascular risk, attributed to hormonal imbalance, altered coagulation, and metabolic disturbance.
Testosterone replacement therapy (TRT) may partially improve metabolic and bone-related outcomes but has "complex" and unresolved effects on cardiovascular and thrombotic risk.
X-linked immune gene dosage effects are proposed to drive higher susceptibility to autoimmune disease.
Neurocognitive and psychiatric features cited include language impairment, executive dysfunction, and increased mood disorder susceptibility.
The review introduces an INSL3-mediated bone-testicular axis and osteocalcin-driven endocrine crosstalk as emerging (not established) mechanistic concepts.
Accelerated epigenetic ageing is mentioned as an emerging finding in KS.
Study Quality
This is a narrative review, not a systematic review or meta-analysis, despite MeSH indexing that might suggest otherwise. There is no described search strategy, no PRISMA-style methodology, no inclusion/exclusion criteria, and no quantitative synthesis of effect sizes across the cited literature. Every claim in the abstract and conclusion is qualitative ("increased risk," "may partially ameliorate," "remain complex") with no accompanying numbers, confidence intervals, or citations to the primary studies underlying each claim as presented here. Single-author narrative reviews are inherently more vulnerable to selective citation and interpretive bias than systematic reviews with predefined protocols and multiple independent reviewers.
Red Flags
No systematic search methodology or PRISMA framework described for a review claiming to be "updated and integrative."
Single author, single institution — no independent verification of literature selection.
Every quantitative claim in the source material (thromboembolic risk, autoimmune risk, cognitive impairment rates) is stated qualitatively without effect sizes, sample sizes, or confidence intervals in the abstract or conclusion.
"Emerging concepts" (INSL3-bone axis, osteocalcin crosstalk, epigenetic ageing) are presented as established mechanisms worth clinical attention despite being explicitly labeled preliminary.
The 75% underdiagnosis figure is repeated as a headline statistic without a cited source study or denominator population described in the available text.
Strengths
Synthesizes a genuinely underserved topic: most KS literature focuses narrowly on hypogonadism and infertility, and this attempts a broader systems view.
Explicitly flags that TRT does not resolve the full systemic burden of KS, avoiding the trap of treating testosterone as a cure-all.
Acknowledges karyotypic heterogeneity and calls for individualized management intensity rather than one-size-fits-all recommendations.
No disclosed conflicts of interest or industry funding.
Verdict
This is a useful map of where KS research is heading, not a rigorous evaluation of the evidence behind it. Treat every claim here as a pointer to go read the primary studies, since the review itself supplies no effect sizes, no methodology, and no meta-analytic weighting to distinguish well-supported findings (metabolic and bone effects of TRT) from speculative ones (osteocalcin crosstalk, epigenetic ageing). Worth skimming for research directions, not worth citing as evidence on its own.